問卷

TPIDB > Search Result > Study Site

Study Site



National Taiwan University Hospital

  • 2,600

    Total Beds

  • 1,008

    Total Doctors

  • linsinjie@ntuh.gov.tw
  • 100Taipei CityJhong Jheng7 Chung Shan S. Rd.,Zhongzheng

篩選

List

3103Cases

2013-12-01 - 2022-12-31

Phase III

A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Tenofovir Alafenamide (TAF) 25 mg QD versus Tenofovir Disoproxil Fumarate (TDF) 300 mg QD for the Treatment of HBeAg-Negative, Chronic Hepatitis B
  • Condition/Disease

    Chronic Hepatitis B

  • Test Drug

    1.Tenofovir Alafenamide (TAF, GS-7340)、 2.Tenofovir Disoproxil Fumarate (TDF, Viread®)

Participate Sites
8Sites

Terminated8Sites

2013-11-01 - 2021-12-31

Phase III

Efficacy, Immunogenicity, and Safety Study of Clostridium difficile Toxoid Vaccine in Subjects at Risk for C. difficile Infection
  • Condition/Disease

    C. difficile Infection

  • Test Drug

    C. difficile Toxoid Vaccine

Participate Sites
7Sites

Terminated7Sites

2011-05-01 - 2014-12-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

2011-09-01 - 2013-12-31

Others

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

2019-01-01 - 2020-02-05

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

2022-01-01 - 2025-12-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Recruiting2Sites

2014-02-01 - 2016-01-30

Others

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Terminated7Sites

2014-01-01 - 2016-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Terminated8Sites

2018-01-01 - 2019-12-31

Others

A TSHRN1201 Sub-study-To Evaluate the Effects of add-on Ranolazine on Exercise Tolerance and Angina Frequency in Patients With Stable Angina Pectoris.
  • Condition/Disease

    Angina

  • Test Drug

    Ranolazine

Participate Sites
3Sites

Terminated3Sites

謝宜璋
Linkou Chang Gung Medical Foundation

Division of Cardiovascular Diseases

2012-05-15 - 2014-04-14

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Terminated9Sites